<p>西氏醫藥服務（NYSE:WST - 獲取免費報告）的股票在週二的報告中被 Stephens 重申了 “增持” 評級，Benzinga 報道。他們目前對該醫療器械供應商的股票設定了 360.00 美元的目標價。Stephens 的目標價表明該股票相較於前一交易日收盤價有 13.97% 的潛在上漲空間。</p>
<ul>
<li>3 只有潛力增加股息的股息冠軍</li>
</ul>
<p>其他一些分析師也對該股票發表了看法。Evercore 在 4 月 24 日的報告中重申了對西氏醫藥服務股票的 “跑贏大盤” 評級。摩根士丹利將西氏醫藥服務的目標價從 315.00 美元上調至 325.00 美元，並在週五的報告中給予該公司 “持平” 評級。德意志銀行在 2 月 13 日的報告中重申了 “買入” 評級，並對西氏醫藥服務的股票設定了 315.00 美元的目標價。巴克萊在 4 月 27 日的報告中將西氏醫藥服務的目標價從 275.00 美元上調至 310.00 美元，並給予該股票 “持平” 評級。最後，Zacks Research 在 5 月 13 日的報告中將西氏醫藥服務的評級從 “持有” 上調至 “強力買入”。兩位投資分析師給予該股票 “強力買入” 評級，九位給予 “買入” 評級，三位給予 “持有” 評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，共識目標價為 327.60 美元。</p>
<p><strong>查看我們關於 WST 的最新研究報告</strong></p>
<h2>西氏醫藥服務股票表現</h2>
<ul>
<li>今年哪些因素將推動標準普爾 500 指數表現？</li>
</ul>
<p>西氏醫藥服務的股票在週二開盤價為 315.87 美元。該公司的債務與股本比率為 0.07，流動比率為 2.71，速動比率為 2.04。該公司的市值為 223.2 億美元，市盈率為 42.23，市盈增長比率為 2.70，貝塔係數為 1.18。該公司的 50 日簡單移動平均線為 285.07 美元，200 日簡單移動平均線為 267.94 美元。西氏醫藥服務的 52 周低點為 206.19 美元，52 周高點為 330.88 美元。</p>
<p>西氏醫藥服務（NYSE:WST - 獲取免費報告）最近在 4 月 23 日發佈了季度財報。該醫療器械供應商報告本季度每股收益為 2.13 美元，超出分析師一致預期的 1.68 美元，超出幅度為 0.45 美元。該季度的營業收入為 8.449 億美元，而分析師預期為 7.7968 億美元。西氏醫藥服務的淨利潤率為 16.85%，股本回報率為 19.03%。與去年同期相比，西氏醫藥服務本季度的收入增長了 21.0%。去年同期，該公司的每股收益為 1.45 美元。西氏醫藥服務已將 2026 財年的指導目標設定為每股收益 8.400-8.750 美元，2026 年第二季度的指導目標設定為每股收益 2.050-2.120 美元。賣方分析師預測西氏醫藥服務在當前財年將實現每股收益 8.6 美元。</p>
<ul>
<li>至少有 30 年股息增長的醫療保健股票</li>
</ul>
<p>西氏醫藥服務宣佈其董事會已於 2 月 17 日授權一項股票回購計劃，允許公司回購 10 億美元的流通股。該回購授權允許該醫療器械供應商通過公開市場購買最多 5.6% 的股份。股票回購計劃通常表明公司的管理層認為其股票被低估。</p>
<h2>內部人士下注</h2>
<p>在其他新聞中，首席會計官 Chad Winters 在 4 月 27 日的交易中出售了 896 股西氏醫藥服務的股票。這些股票的平均售價為 300.67 美元，總交易額為 269,400.32 美元。交易後，首席會計官直接持有該公司 1,523 股股票，價值 457,920.41 美元。這筆交易代表其持股比例減少了 37.04%。該銷售在向 SEC 提交的文件中披露，文件可通過此超鏈接獲取。此外，副總裁 Annette F. Favorite 在 4 月 27 日的交易中出售了 2,817 股西氏醫藥服務的股票。該股票的平均售價為 305.20 美元，總交易額為 859,748.40 美元。交易後，副總裁直接持有該公司 16,828 股股票，價值約 5,135,905.60 美元。這代表其持股比例減少了 14.34%。該銷售的 SEC 文件提供了更多信息。公司內部人士持有公司股票的 0.60%。</p>
<h2>對西氏醫藥服務的對沖基金看法</h2>
<p>一些對沖基金和其他機構投資者最近對其在 WST 的持倉進行了調整。Elyxium Wealth LLC 在第四季度購買了西氏醫藥服務的新股份，價值 25,000 美元。Bayban 在第四季度購買了西氏醫藥服務的新股份，價值 27,000 美元。Private Trust Co. NA 在第四季度將其在西氏醫藥服務的持倉提高了 156.4%。Private Trust Co. NA 現在持有該醫療器械供應商 100 股股票，價值 28,000 美元，此前在上個季度又購買了 61 股。DV Equities LLC 在第四季度購買了西氏醫藥服務的新股份，價值 28,000 美元。最後，Cornerstone Planning Group LLC 在第一季度將其在西氏醫藥服務的持倉提高了 90.9%。Cornerstone Planning Group LLC 現在持有該醫療器械供應商 105 股股票，價值 26,000 美元，此前在上個季度又購買了 50 股。93.90% 的股票由機構投資者持有。</p>
<h2>西氏醫藥服務公司簡介</h2>
<p>（獲取免費報告）</p>
<p>西氏醫藥服務公司是一家全球開發和製造組件、系統及服務的公司，旨在實現可注射藥物的封裝和輸送。該公司專注於為製藥和生物技術行業提供高質量的包裝和輸送解決方案，生產用於疫苗、生物製劑和其他可注射療法的主要藥物包裝組件和專業藥物輸送設備。西氏以其彈性密封件、密封條和聚合物組件而聞名，這些產品能夠保持無菌性並與敏感藥物配方兼容。</p>
<p>除了組件製造，西氏還提供工程化輸送系統和產品生命週期內的支持服務。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，而非西氏醫藥服務</li>
<li>投資 Pony AI 股票的五個理由——以及一個等待的理由</li>
<li>SpaceX IPO 是否會讓這五隻公共航天股票進入更高的軌道？</li>
<li>Palantir 的無人機順風助力其國防 AI 故事重新引起投資者關注</li>
<li>為什麼一隻鮮為人知的 ETF 正在利用 AI 芯片短缺</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元於西氏醫藥服務嗎？</h2>
<p>在考慮西氏醫藥服務之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，而西氏醫藥服務並不在名單上。</p>
<p>雖然西氏醫藥服務目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

西氏醫藥服務

<p>斯蒂芬斯重申了對西氏醫藥服務（West Pharmaceutical Services，WST）的 “增持” 評級，目標價為 360 美元，意味着有 13.97% 的上漲空間。其他分析師如 Evercore、摩根士丹利和德意志銀行也維持了積極的評級或提高了目標價。WST 最近以每股收益 2.13 美元和 8.449 億美元的收入超出了第一季度的盈利預期。該公司授權了一項 10 億美元的股票回購計劃。最近 CAO Chad Winters 和副總裁 Annette Favorite 的內部銷售被披露</p>

<p>West Pharmaceutical Services (NYSE:WST - Get Free Report)'s stock had its &#34;overweight&#34; rating reaffirmed by Stephens in a report issued on Tuesday,Benzinga reports. They presently have a $360.00 price objective on the medical instruments supplier's stock. Stephens' price objective indicates a potential upside of 13.97% from the stock's previous close.</p>
<div class="lb-trans"><p>西氏醫藥服務（NYSE:WST - 獲取免費報告）的股票在週二的報告中被 Stephens 重申了 “增持” 評級，Benzinga 報道。他們目前對該醫療器械供應商的股票設定了 360.00 美元的目標價。Stephens 的目標價表明該股票相較於前一交易日收盤價有 13.97% 的潛在上漲空間。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潛力增加股息的股息冠軍</li>
</ul>
</div><p>A number of other analysts have also weighed in on the stock. Evercore reissued an &#34;outperform&#34; rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Morgan Stanley raised their price target on shares of West Pharmaceutical Services from $315.00 to $325.00 and gave the company an &#34;equal weight&#34; rating in a report on Friday. Deutsche Bank Aktiengesellschaft reissued a &#34;buy&#34; rating and issued a $315.00 price target on shares of West Pharmaceutical Services in a report on Friday, February 13th. Barclays lifted their target price on shares of West Pharmaceutical Services from $275.00 to $310.00 and gave the stock an &#34;equal weight&#34; rating in a report on Monday, April 27th. Finally, Zacks Research raised shares of West Pharmaceutical Services from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $327.60.</p>
<div class="lb-trans"><p>其他一些分析師也對該股票發表了看法。Evercore 在 4 月 24 日的報告中重申了對西氏醫藥服務股票的 “跑贏大盤” 評級。摩根士丹利將西氏醫藥服務的目標價從 315.00 美元上調至 325.00 美元，並在週五的報告中給予該公司 “持平” 評級。德意志銀行在 2 月 13 日的報告中重申了 “買入” 評級，並對西氏醫藥服務的股票設定了 315.00 美元的目標價。巴克萊在 4 月 27 日的報告中將西氏醫藥服務的目標價從 275.00 美元上調至 310.00 美元，並給予該股票 “持平” 評級。最後，Zacks Research 在 5 月 13 日的報告中將西氏醫藥服務的評級從 “持有” 上調至 “強力買入”。兩位投資分析師給予該股票 “強力買入” 評級，九位給予 “買入” 評級，三位給予 “持有” 評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，共識目標價為 327.60 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on WST</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 WST 的最新研究報告</strong></p>
</div><h2>West Pharmaceutical Services Stock Performance</h2>
<div class="lb-trans"><h2>西氏醫藥服務股票表現</h2>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>今年哪些因素將推動標準普爾 500 指數表現？</li>
</ul>
</div><p>Shares of West Pharmaceutical Services stock opened at $315.87 on Tuesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.71 and a quick ratio of 2.04. The firm has a market cap of $22.32 billion, a P/E ratio of 42.23, a P/E/G ratio of 2.70 and a beta of 1.18. The firm has a 50 day simple moving average of $285.07 and a 200 day simple moving average of $267.94. West Pharmaceutical Services has a fifty-two week low of $206.19 and a fifty-two week high of $330.88.</p>
<div class="lb-trans"><p>西氏醫藥服務的股票在週二開盤價為 315.87 美元。該公司的債務與股本比率為 0.07，流動比率為 2.71，速動比率為 2.04。該公司的市值為 223.2 億美元，市盈率為 42.23，市盈增長比率為 2.70，貝塔係數為 1.18。該公司的 50 日簡單移動平均線為 285.07 美元，200 日簡單移動平均線為 267.94 美元。西氏醫藥服務的 52 周低點為 206.19 美元，52 周高點為 330.88 美元。</p>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.68 by $0.45. The business had revenue of $844.90 million during the quarter, compared to analyst estimates of $779.68 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. West Pharmaceutical Services's revenue for the quarter was up 21.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Sell-side analysts predict that West Pharmaceutical Services will post 8.6 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>西氏醫藥服務（NYSE:WST - 獲取免費報告）最近在 4 月 23 日發佈了季度財報。該醫療器械供應商報告本季度每股收益為 2.13 美元，超出分析師一致預期的 1.68 美元，超出幅度為 0.45 美元。該季度的營業收入為 8.449 億美元，而分析師預期為 7.7968 億美元。西氏醫藥服務的淨利潤率為 16.85%，股本回報率為 19.03%。與去年同期相比，西氏醫藥服務本季度的收入增長了 21.0%。去年同期，該公司的每股收益為 1.45 美元。西氏醫藥服務已將 2026 財年的指導目標設定為每股收益 8.400-8.750 美元，2026 年第二季度的指導目標設定為每股收益 2.050-2.120 美元。賣方分析師預測西氏醫藥服務在當前財年將實現每股收益 8.6 美元。</p>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增長的醫療保健股票</li>
</ul>
</div><p>West Pharmaceutical Services declared that its Board of Directors has authorized a share repurchase program on Tuesday, February 17th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical instruments supplier to repurchase up to 5.6% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's leadership believes its stock is undervalued.</p>
<div class="lb-trans"><p>西氏醫藥服務宣佈其董事會已於 2 月 17 日授權一項股票回購計劃，允許公司回購 10 億美元的流通股。該回購授權允許該醫療器械供應商通過公開市場購買最多 5.6% 的股份。股票回購計劃通常表明公司的管理層認為其股票被低估。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer directly owned 1,523 shares of the company's stock, valued at $457,920.41. This trade represents a 37.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the transaction, the vice president directly owned 16,828 shares in the company, valued at approximately $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，首席會計官 Chad Winters 在 4 月 27 日的交易中出售了 896 股西氏醫藥服務的股票。這些股票的平均售價為 300.67 美元，總交易額為 269,400.32 美元。交易後，首席會計官直接持有該公司 1,523 股股票，價值 457,920.41 美元。這筆交易代表其持股比例減少了 37.04%。該銷售在向 SEC 提交的文件中披露，文件可通過此超鏈接獲取。此外，副總裁 Annette F. Favorite 在 4 月 27 日的交易中出售了 2,817 股西氏醫藥服務的股票。該股票的平均售價為 305.20 美元，總交易額為 859,748.40 美元。交易後，副總裁直接持有該公司 16,828 股股票，價值約 5,135,905.60 美元。這代表其持股比例減少了 14.34%。該銷售的 SEC 文件提供了更多信息。公司內部人士持有公司股票的 0.60%。</p>
</div><h2>Hedge Funds Weigh In On West Pharmaceutical Services</h2>
<div class="lb-trans"><h2>對西氏醫藥服務的對沖基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in WST. Elyxium Wealth LLC bought a new stake in West Pharmaceutical Services in the 4th quarter valued at $25,000. Bayban bought a new stake in West Pharmaceutical Services in the 4th quarter valued at $27,000. Private Trust Co. NA lifted its position in West Pharmaceutical Services by 156.4% in the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 61 shares in the last quarter. DV Equities LLC bought a new stake in West Pharmaceutical Services in the 4th quarter valued at $28,000. Finally, Cornerstone Planning Group LLC lifted its position in West Pharmaceutical Services by 90.9% in the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier's stock valued at $26,000 after acquiring an additional 50 shares in the last quarter. 93.90% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近對其在 WST 的持倉進行了調整。Elyxium Wealth LLC 在第四季度購買了西氏醫藥服務的新股份，價值 25,000 美元。Bayban 在第四季度購買了西氏醫藥服務的新股份，價值 27,000 美元。Private Trust Co. NA 在第四季度將其在西氏醫藥服務的持倉提高了 156.4%。Private Trust Co. NA 現在持有該醫療器械供應商 100 股股票，價值 28,000 美元，此前在上個季度又購買了 61 股。DV Equities LLC 在第四季度購買了西氏醫藥服務的新股份，價值 28,000 美元。最後，Cornerstone Planning Group LLC 在第一季度將其在西氏醫藥服務的持倉提高了 90.9%。Cornerstone Planning Group LLC 現在持有該醫療器械供應商 105 股股票，價值 26,000 美元，此前在上個季度又購買了 50 股。93.90% 的股票由機構投資者持有。</p>
</div><h2>West Pharmaceutical Services Company Profile</h2>
<div class="lb-trans"><h2>西氏醫藥服務公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.</p>
<div class="lb-trans"><p>西氏醫藥服務公司是一家全球開發和製造組件、系統及服務的公司，旨在實現可注射藥物的封裝和輸送。該公司專注於為製藥和生物技術行業提供高質量的包裝和輸送解決方案，生產用於疫苗、生物製劑和其他可注射療法的主要藥物包裝組件和專業藥物輸送設備。西氏以其彈性密封件、密封條和聚合物組件而聞名，這些產品能夠保持無菌性並與敏感藥物配方兼容。</p>
</div><p>In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.</p>
<div class="lb-trans"><p>除了組件製造，西氏還提供工程化輸送系統和產品生命週期內的支持服務。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>5 Reasons to Pony Up for Pony AI Stock—and 1 Reason to Wait</li>
<li>Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?</li>
<li>Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for Investors</li>
<li>Why 1 Little-Known ETF Is Riding the AI Chip Shortage</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非西氏醫藥服務</li>
<li>投資 Pony AI 股票的五個理由——以及一個等待的理由</li>
<li>SpaceX IPO 是否會讓這五隻公共航天股票進入更高的軌道？</li>
<li>Palantir 的無人機順風助力其國防 AI 故事重新引起投資者關注</li>
<li>為什麼一隻鮮為人知的 ETF 正在利用 AI 芯片短缺</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元於西氏醫藥服務嗎？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮西氏醫藥服務之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，而西氏醫藥服務並不在名單上。</p>
</div><p>While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然西氏醫藥服務目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

West Pharmaceutical Services' (WST) "Overweight" Rating Reiterated at Stephens

Market Beat

摩根士丹利

德意志銀行

巴克萊銀行

標普 500 指數

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

Stephens 重申了對西氏醫藥服務（WST）的 “增持” 評級